Purpose The pharmacology, safety, efficacy, pharmacokinetics, pharmacodynamics, current place in therapy, and potential future therapeutic uses of inhaled aztreonam are reviewed. Conclusion ...
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...
In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam-avibactam + metronidazole or meropenem ± colistin for 5 to 14 days of therapy. The primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback